The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended GlaxoSmithKline’s Hycamtin as a second-line treatment for small-cell lung cancer (SCLC).

The final appraisal determination (FAD) recommends the use of oral Hycamtin as an option for people with relapsed SCLC who are no longer eligible for first-line treatment.

With this approval, oral topotecan becomes the first treatment specifically proven for relapsed SCLC patients, who previously had very limited treatment options.

GSK UK General Manager Simon Jose said that this was a proven treatment that could improve survival in patients with this aggressive disease.

“We hope that NHS Trusts ensure there is a fast uptake of this guidance so that patients are able to get access to oral topotecan as soon as they require it,” he said.

Topotecan is a chemotherapy agent that works by slowing down or stopping cancer cells from reproducing.